Materials and methods

Setting
The study population consisted of all members of Discovery Health medical aid as at the end of 2011. The Discovery Health screening programme offers a paid screening benefit to its members for mammograms, Pap smears, HIV tests, glaucoma screening, prostatespecific antigen (PSA) for prostate cancer screening, random glucose and cholesterol tests, 'flu vaccines and pneumococcal vaccines, irrespective of the type of medical plan members belong to. Other preventive screening tests are not fully paid for and have some form of co-payments; these include colorectal cancer and osteoporosis screening. The Human Research Ethics Committee of the University of the Witwatersrand granted ethical clearance for the study (certificate No. M120854).
Methods
Eligibility criteria for the tests evaluated were adapted from the US Preventive Services Task Force Recommendations and are outlined in Table 1 . Some preventive tests have clear recommendations for screening frequency, while others do not. For this study, screening for a disease was characterised as having had at least one of the screening tests outlined in Table 1 for the calendar year of 2011 (annual average). It is therefore not an evaluation of whether members' screening behaviour adheres to screening recommendations. The study also did not evaluate differences between covered and noncovered tests, but simply the provincial variation in annual screening rates. Each member was assigned to one of the nine provinces according to a valid address in that province for the duration of 2011.
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Statistical analyses
The study was a cross-sectional descriptive analysis of the annual screening rate of all eligible medical aid members in 2011 across all nine provinces. The mean screening rate for each test was compared between provinces using Student's t-test for unpaired samples, with Gauteng as the baseline. Variation between provinces was described using ratios of differences. All analyses were conducted using STATA 12.0 (StataCorp, USA).
Results
Screening rates for a total of 1 889 447 members were evaluated for the year 2011. Descriptive statistics of the study sample by province are reported in Table 2 . The provincial screening rates are shown in Table 3 .
Gauteng had the highest annual screening rate for cholesterol at 27.5% of eligible insured members, and the Northern Cape the lowest at 13.4%. Gauteng's screening rate for cholesterol was also significantly higher than those of the other provinces, figures for which were between 0.93 (Western Cape) and 0.49 (Northern Cape) times lower than Gauteng (p<0.001). The variations in screening rates are shown in Table 4 . The highest annual screening rate for glucose was 29.7% (Mpumalanga), although this was not significantly different from Gauteng's 29.6% (p=0.97). The lowest screening rate for glucose was in the Northern Cape (17.5%), with a variation of 0.59 times lower than Gauteng. KwaZulu-Natal had a 0.84 times lower screening for cholesterol than Gauteng.
Prostate cancer screening had the highest uptake of all preventive screening tests. Around 37.7% of males over 50 years old had had a PSA test in Gauteng, versus a low of 25.6% of males in the Northern Cape. Gauteng had the highest screening rate for prostate cancer of all the provinces (p<0.001), and screening rates for prostate cancer ranged from 0.90 to 0.68 times lower in other provinces compared with Gauteng.
The Western Cape had the highest cervical cancer screening rate (p<0.001), with 23.1% of all eligible females having had a Pap smear versus only 13.1% of females in the Northern Cape. The screening rate for cervical cancer in the Western Cape was 1.03 times higher than that in Gauteng, while the rate was 0.55 times lower in Limpopo than in Gauteng.
The highest screening rate for breast cancer was in Gauteng (p<0.001), with 17.0% of eligible females having had a mammogram, while the lowest rate of 9.4% was in the Northern Cape. Rates for mammograms ranged from 0.95 to 0.60 times lower in the other provinces compared with Gauteng.
HIV screening had the largest variation of all the screening tests. Gauteng had the highest rate (p<0.001), with 12.8% of members having had the test, and the lowest rate was in the Northern Cape, where only 4.8% of members had been tested in 2011. Northern Cape had a 0.38 times lower screening rate than Gauteng.
Colorectal cancer screening, currently not part of the paid screening benefit, had the lowest rate. The Eastern Cape (0.7%) had the highest rate (p<0.001), while the lowest rate (0.2%) was in Limpopo. The Eastern Cape's screening rate was 1.17 times higher than Gauteng's and 3.5 times higher than Limpopo's.
Osteoporosis screening, which is also not part of the paid screening benefit, had the highest rate in Gauteng (p<0.001), with 7.9% of members undergoing screening, and the lowest rate in the Northern Cape (2.2%). Rates of screening for osteoporosis were between 0.82 and 0.28 times lower in the other eight provinces than in Gauteng.
Screening rates for all the provinces are presented in Fig. 1 , with Gauteng shown in black. 
Discussion
Use of screening services in this SA medical aid population is low and far below international benchmark targets of 93.0% for cervical cancer, 70.5% for colorectal cancer, 81.1% for breast cancer and 82.1% for cholesterol screening. [14] Surveys of screening rates in comparable populations showed that 68% of adults in the USA reported having had a cholesterol test in the preceding 5 years, and more than 75% of females aged 40 years and older had had a mammogram in the preceding 2 years; [15] in European countries (Germany, the Netherlands, England and Italy), between 61% and 79% of females over 50 years were screened for breast cancer biennially. [15, 16] Screening rates among medically insured individuals tend to be slightly higher than in the uninsured, with rates of up to 77.6% for mammograms, 91.5% for Pap smears, 85.5% for cholesterol tests and 50.9% for colorectal cancer. [17] There is considerable variation in utilisation of screening services between provinces in the SA insured population. Screening rates for chronic diseases of lifestyle varied from 30% to 50% lower in the Northern Cape and Limpopo compared with Gauteng and the Western Cape. Cancer screening ranged from 45% to 5% lower in some provinces compared with Gauteng. Rates of HIV screening in the Free State, North West and the Northern Cape were less than half that in Gauteng. This is consistent with findings of others that urbanised areas achieved better uptake of screening services. [18] The variation in utilisation of screening services seen in this medically insured population may not be unusual. Even among medical aid members, where the costs of screening tests are paid for, and in settings where screening facilities are easily accessible, researchers have found poor uptake of services. [19, 20] This confirms the previous conclusion that access alone is not the only driver of healthcare utilisation disparities. [1] Access to facilities may be better in the more urbanised provinces and may play a role in the unequal use of preventive services, together with several other individual and provider factors. [6, 21] Further research is required to fully understand the reasons for inequitable use of preventive services across the nine provinces in this health insured population.
This study is limited by the fact that it focused only on annual uptake of screening services and not on adherence to screening guidelines, disease detection rates or treatment/management outcomes. Further research is necessary to analyse available data over longer time frames in order to establish the proportion of people who have availed themselves of recommended screening, as well as their health outcomes. Another limitation is that inferences in respect of screening rates can be drawn only on other groups within SA with similar health insurance coverage and not on the uninsured population. It is expected that the general uninsured population screening rate would be much lower than those of the health-insured population. Future research agendas should include comprehensive evaluation of all preventive screening services utilisation (CDL, cancers and HIV) in the uninsured population, with a view to establishing eligibility criteria and creating targets for utilisation of services at various national, provincial and district levels and strengthening national databases, given the imminent introduction of National Health Insurance. This study provides some indication of screening patterns at a national level and the variation that persists in this privately insured population. The strength of this study is that it analysed the entire health-insured population's screening activity over a 1-year period at both national and provincial level and therefore accurately represents their annual screening practices compared with survey data estimations.
Conclusion
This is the first look at national screening practices in a South African population. In this health-insured population, screening varies greatly between provinces for CDL, cancers and HIV. Screening rates in the larger uninsured South African population may be even lower. We found that the better-resourced provinces had higher screening rates. The variations between the provinces deserve further exploration in order to evaluate the effect of resource allocation, access to care, provider factors and socio-demographic characteristics that may impact on screening rates.
